Alcon stock gains 1.27% after tighter 2026 outlook
Published on 11/11/2026 at 17:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat changed for investors
- Alcon reported third-quarter sales growth across Surgical and Vision Care.
- Management tightened its 2026 sales, margin and core earnings outlook.
- A large PowerVision charge depressed nine-month reported earnings, while core results improved.
Alcon reported stronger third-quarter operating performance on Tuesday, November 10, while narrowing its full-year 2026 outlook. In its media release, the company said sales for the three months ended September 30 rose 5 percent to 2.717 billion US dollars.
Alcon stock traded at 64.03 euros on Lang & Schwarz at 17:02 CET on Wednesday, November 11, 2026, 1.27 percent above the 63.23 euros cited in the latest report at 10:44 CET on the same day.
Growth reaches both core divisions
Surgical sales increased 4 percent to 1.480 billion US dollars. Equipment and other sales rose 11 percent to 269 million US dollars, while implantables declined 2 percent to 422 million US dollars as competitive pressure affected intraocular lens sales in the United States.
Vision Care sales advanced 6 percent to 1.237 billion US dollars. Contact lenses grew 4 percent, and ocular health sales increased 8 percent to 500 million US dollars, supported by dry-eye products including Tryptyr and Systane.
Guidance narrows after mixed earnings
Reported operating income rose 15 percent to 381 million US dollars, lifting the operating margin to 14.0 percent from 12.8 percent. Core operating income, a non-IFRS measure, increased 13 percent to 591 million US dollars, while core operating margin reached 21.8 percent from 20.2 percent.
Alcon now expects 2026 sales growth of approximately 6 percent on a constant-currency basis, compared with the previous range of 5 to 7 percent. The company also narrowed its core operating-margin improvement target to 100 to 150 basis points and its core diluted EPS growth forecast to 12 to 14 percent.
Investors must distinguish the stronger core performance from reported nine-month earnings. Diluted EPS for the first nine months fell 40 percent to 0.92 US dollars, mainly because of a non-cash charge linked to discontinued PowerVision programs. Core diluted EPS rose 14 percent to 2.60 US dollars.
Alcon Inc. key figures
- Company: Alcon Inc.
- ISIN: CH0432492467
- Ticker: ALC
- Listings: SIX Swiss Exchange and New York Stock Exchange
- Lang & Schwarz quote: 64.03 euros, Wednesday, November 11, 2026, at 17:02 CET
- Third-quarter sales: 2.717 billion US dollars
- Core diluted EPS: 0.91 US dollars
Swiss equities provide the broader market context in current SMI market reports.
